http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
난용성 약물의 용출 증가(제4보) -재결정법에 의한 푸로세미드의 미세화-
고익배,신상철,오인준,Koh, Ik-Bae,Shin, Sang-Chul,Oh, In-Joon 한국약제학회 1988 Journal of Pharmaceutical Investigation Vol.18 No.2
The size of furosemide was reduced by the recrystallization method in order to increase the dissolution rate of the drug. Surfactants or hydrophilic polymers were used to suppress the aggregation in the crystal formation-growth process of microparticles by dispersing action. Dissolution rate of microparticles increased remarkably due to the size reduction of microparticle. The particle size decreased with increasing the concentration of the drug and the dispersing agents, i.e., surfactants or hydrophilic polymers. No polymorphic transition occurred during the microcrystallization process, but the habit of crystal formation was altered in the case of anionic surfactant.
그리세오풀빈-페노바르비탈 상호작용(I) -페노바르비탈 전처리 Rat에 있어서 그리세오풀빈의 생체내 동태-
고익배(Ik Bae Koh),신상철(Sang Chul Shin),이용복(Yong Bok Lee) 대한약학회 1986 약학회지 Vol.30 No.6
Effects of phenobarbital on the pharmacokinetics of griseofulvin were studied in rats. Phenobarbital was administered orally for five days at the dose of 75mg/kg/day. Absolute bioavaiability of oral griseofulvin was significantly(p<0.005) reduced but total clearance(CLs) was not changed by phenobarbital pretreatment. Absorption rate constant(Ka) and maximum plasma concentration(Cmax) were significantly(pmax) of griseofulvin was significantly(p<0.05) increased by phenobarbital pretreatment. Changed pharmacokinetics of griseofulvin seemed not to be due to induced enzyme activity by phenobarbital but to reduced GI absorption of griseofulvin.
랫트에 있어서 페노바르비탈 전처리가 딜티아젬의 생체내 동태에 미치는 영향
이용복,고익배,이민화,Lee, Yong-Bok,Koh, Ik-Bae,Lee, Min-Hwa 한국약제학회 1992 Journal of Pharmaceutical Investigation Vol.22 No.3
The influence of phenobarbital (PB) pretreatment (75 mg/kg/day, i.p. for 4 days) on the pharmacokinetics of diltiazem (DTZ) and its metabolite, desacetyldiltiazem (DAD), was investigated in rats. DTZ was injected via femoral (3 mg/kg) or portal (10 mg/kg) vein to the control and PB-pretreated rats. DAD was also injected separately via femoral (3 mg/kg) vein to both groups of rats. The intrinsic hepatic plasma clearance of DTZ was found to be significantly increased (6.8-fold) by the PB pretreatment. However, the fraction of an intravenous DTZ dose converted to DAD $(F_mi)$ was only slightly (6%) increased and calculated metabolic rate constant of DTZ to DAD was not affected by the pretreatment. On the other hand, plasma free fraction of DTZ was increased (1.8-fold) from $4.24{\pm}0.25%$ to $7.45{\pm}0.54%$ by the pretreatment. However, the l.8-fold increase in the free fraction of DTZ would not explain the 6.8-fold increase in the hepatic intrinsic clearance of DTZ. Therefore, the increase in either the hepatic blood flow or the metabolism other than to DAD was expected as the probable mechanism(s) of the increased hepatic clearance of DTZ. Sequential metabolism of DAD to further metabolites, however, would be a more potential cause of the apparently unchanged metabolism of DTZ to DAD by the PB-pretreatment.
Effect of Polyisobutylene and Sealant Treatments on Ethylcellulose-Walled Methyldopa Microcapsules
신상철,고익배,Shin, Sang-Chul,Koh, Ik-Bae 한국약제학회 1989 Journal of Pharmaceutical Investigation Vol.19 No.1
For the prevention of the aggregation during microencapsulation, the effects and role of polyisobutylene(PIB), as a protective colloid, were studied. The effects of sealant treatment on the microencapsulation were studied. Methyldopa was microencapsulated with ethylcellulose (EC) by polymer deposition from cyclohexane by temperature change using PIB. The EC-microencapsulated methyldopa was sealed with spermaceti. The dissolution of methyldopa was influenced by the drug to wall ratio. When PIB was used, low aggregation of microcapsules occurred and the surface was smooth with a few pores. Treatment of microcapsules with spermaceti retarded the release of methyldopa, the release being affected by the percentage of sealant used and the particle size of the product.
시메티딘이 간혈류량에 미치는 영향 - Rat에 있어서 Indocyanine Green의 체내 동태를 중심으로 -
이용복,고익배,Lee, Yong-Bok,Koh, Ik-Bae 한국임상약학회 1993 한국임상약학회지 Vol.3 No.2
The influence of cimetidine pretreatment(100mg/kg, single i.p.) on the hepatic blood flow was investigated using pharmacokinetic parameters of indocyanine green(ICG) in the rat on the basis of hepacc perfusion-limited model. ICG(1mg/kg) was respectively administered via femoral and portal vein to the control and to the cimetidine-pretreated rats. The rate constant K12, K20 and the systemic clearance(CLt) of ICG were significantly(p<0.05) decreased ill the cimetidine-pretrea-to(B rats, but no significant diffirences were observed in hematocrit and liver weight. The biliary excretion rates of ICG were also decreased regardless of the route of administration in the cimetidine-pretreated rats. And also the hepatic blood flow in rats was decreased about $16\%$ by cimetidine. It may be concluded that the decreased hepatic blood flow with cimetidine mainly contributed to the decreased hepatic uptake and the decreased systemic clearance of ICG.
신상철,고익배,Shin, Sang-Chul,Koh, Ik-Bae 한국약제학회 1991 Journal of Pharmaceutical Investigation Vol.21 No.4
Microencapsulation of sodium ascorbate with cellulose acetate phthalate(CAP) by coacervation/ phase separation method were carried out. Various factors affecting microencapsulation, i.e., surfactant concentration. CAP concentration, stirring speed and treatment of spermaceti as a sealing agent were studied. Dissolution rate. particle size distribution, surface feature and stability test were investigated. CAP microcapsules prepared using 0.5% span 80 as a surfactant showed smooth and round surfaces. The release of sodium ascorbate was retarded by microencapsulation with CAP and by sealant treatment with spermaceti. When triturated with sodium bicarbonate, CAP microcapsules were more stable than unencapsulated sodium ascorbate under various RH conditions at $37^{\circ}C$.